Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Tradjenta Generic Name & Formulations
Legal Class
Rx
General Description
Linagliptin 5mg; tabs.
Pharmacological Class
Dipeptidyl peptidase-4 (DPP-4) inhibitor.
How Supplied
Tabs—30, 90
Manufacturer
Generic Availability
NO
Mechanism of Action
Increases concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the level of glucagon in the circulation. Inhibits degradation of glucagon-like peptide-1 (GLP-1), which reduces glucagon secretion from pancreatic alpha-cells, resulting in a reduction in hepatic glucose output.
Tradjenta Indications
Indications
Adjunct to diet and exercise in type 2 diabetes mellitus, as monotherapy or combination therapy.
Limitations of Use
Not for treatment of type 1 diabetes. Not studied in patients with a history of pancreatitis.
Tradjenta Dosage and Administration
Adult
5mg once daily.
Children
<18yrs: not established.
Nursing Considerations
Hypoglycemia may occur when used in combination with insulin secretagogue (eg, sulfonylurea) or insulin. Advise patients to seek medical advice promptly during periods of stress such as fevers, trauma, infection, or surgery, as medication requirements may change. HbA1C monitoring is especially useful for evaluating long-term glycemic control.
Tradjenta Contraindications
Not Applicable
Tradjenta Boxed Warnings
Not Applicable
Tradjenta Warnings/Precautions
Warnings/Precautions
Consider risks/benefits in patients with known risk factors for heart failure; monitor for signs/symptoms; evaluate and consider discontinuing if develops. Monitor for signs/symptoms of pancreatitis, serious hypersensitivity reactions, severe joint pain, or bullous pemphigoid; discontinue if suspected or occurs. History of angioedema to other DPP-4 inhibitors. Pregnancy. Nursing mothers.
Tradjenta Pharmacokinetics
Absorption
Absolute bioavailability: ~30%.
Distribution
Mean apparent volume of distribution at steady-state after a single IV dose of linagliptin 5mg: ~1110 L.
Plasma protein bound (concentration-dependent): 99% at 1 nmol/L; 75–89% at ≥30 nmol/L; 70–80% at high concentrations.
Elimination
Enterohepatic (80%), renal (5%). Half-life: ~11 hours.
Tradjenta Interactions
Interactions
Antagonized by strong P-gp or CYP3A4 inducers (eg, rifampin); consider alternatives to linagliptin if used in combination. May need lower doses of the concomitant insulin secretagogue (eg, sulfonylurea) or insulin to reduce risk of hypoglycemia.
Tradjenta Adverse Reactions
Adverse Reactions
Nasopharyngitis, diarrhea, cough, hypoglycemia; hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema, exfoliative skin conditions, bronchial hyperreactivity), myalgia, pancreatitis, severe and disabling arthralgia, bullous pemphigoid.
Tradjenta Clinical Trials
See Literature
Tradjenta Note
Not Applicable
Tradjenta Patient Counseling
See Literature
Images
